Strides gets USFDA nod for generic Oxybutynin Chloride tablets
Company's step-down wholly owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food& Drug Administration (USFDA), Strides said in a filing to BSE.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Chloride | Ditropan | Oxybutynin | Pharmaceuticals | Singapore Health | USA Health